Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells.
Albumins
/ metabolism
Animals
Antibodies, Monoclonal
/ chemistry
Antigens, Neoplasm
/ metabolism
Carbonic Anhydrase IX
/ metabolism
Cell Line, Tumor
Half-Life
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Hypoxia
Mice
Pentetic Acid
Tissue Distribution
Tomography, Emission-Computed, Single-Photon
albumin-binding domain (ABD)
carbonic anhydrase IX (CAIX)
tumor hypoxia
variable domain of heavy chain only antibody (VHH)
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
pubmed:
20
1
2022
medline:
5
10
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Hypoxic areas are present in the majority of solid tumors, and hypoxia is associated with resistance to therapies and poor outcomes. A transmembrane protein that is upregulated by tumor cells that have adapted to hypoxic conditions is carbonic anhydrase IX (CAIX). Therefore, noninvasive imaging of CAIX could be of prognostic value, and it could steer treatment strategies. The aim of this study was to compare variants of CAIX-binding VHH B9, with and without a C-terminal albumin-binding domain with varying affinity (ABD
Identifiants
pubmed: 35044182
doi: 10.1021/acs.molpharmaceut.1c00841
pmc: PMC9533306
doi:
Substances chimiques
Albumins
0
Antibodies, Monoclonal
0
Antigens, Neoplasm
0
Pentetic Acid
7A314HQM0I
Carbonic Anhydrase IX
EC 4.2.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3511-3520Références
Protein Eng Des Sel. 2007 Nov;20(11):569-76
pubmed: 17982179
BMC Cancer. 2014 Feb 26;14:130
pubmed: 24571588
J Control Release. 2020 Jan 10;317:34-42
pubmed: 31734445
Mol Pharm. 2019 Feb 4;16(2):701-708
pubmed: 30550290
Vaccine. 2005 Sep 30;23(41):4926-34
pubmed: 15992972
Curr Opin Biotechnol. 2011 Dec;22(6):868-76
pubmed: 21862310
Mol Imaging. 2012 Feb;11(1):33-46
pubmed: 22418026
Theranostics. 2017 Sep 26;7(17):4322-4339
pubmed: 29158829
J Biol Chem. 2011 Feb 18;286(7):5234-41
pubmed: 21138843
Cancer Res. 2007 Mar 15;67(6):2773-82
pubmed: 17363599
Theranostics. 2021 Mar 13;11(11):5525-5538
pubmed: 33859761
Nucl Med Biol. 2014 May;41 Suppl:e44-8
pubmed: 24530366
J Control Release. 2013 Dec 28;172(3):607-17
pubmed: 24035975
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
J Nucl Med. 2013 Jan;54(1):124-31
pubmed: 23236020
Mol Imaging Biol. 2016 Aug;18(4):535-44
pubmed: 26589824
Radiother Oncol. 2017 Sep;124(3):521-525
pubmed: 28789809
Front Immunol. 2018 Feb 19;9:273
pubmed: 29520274
Biotechnol J. 2014 Sep;9(9):1215-22
pubmed: 24678002
Mol Pharm. 2018 Mar 5;15(3):934-946
pubmed: 29400475
Radiat Res. 1987 Aug;111(2):292-304
pubmed: 3628717
Sci Rep. 2019 Dec 11;9(1):18898
pubmed: 31827111
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2201-2217
pubmed: 30128659
Genomics. 1996 May 1;33(3):480-7
pubmed: 8661007
EJNMMI Res. 2021 Jan 19;11(1):6
pubmed: 33464410
Nanomedicine (Lond). 2015 Jan;10(1):161-74
pubmed: 25597775
Theranostics. 2017 Apr 27;7(7):1928-1939
pubmed: 28638478
Curr Radiopharm. 2015;8(1):32-7
pubmed: 25808959
Front Immunol. 2017 Oct 12;8:1287
pubmed: 29075266
Adv Drug Deliv Rev. 2002 Jun 17;54(4):531-45
pubmed: 12052713
Front Immunol. 2017 Nov 02;8:1442
pubmed: 29163515
Cancer. 1997 Dec 15;80(12 Suppl):2390-7
pubmed: 9406688
J Nucl Med. 2013 Jun;54(6):961-8
pubmed: 23528382
Biochim Biophys Acta. 2013 Dec;1830(12):5526-34
pubmed: 23639804
JAMA Otolaryngol Head Neck Surg. 2015 Mar;141(3):250-6
pubmed: 25554966
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773
Radiother Oncol. 2003 Apr;67(1):3-15
pubmed: 12758235
Bioconjug Chem. 2019 Mar 20;30(3):487-502
pubmed: 30616340